IMBiologics
IMBiologics researches and develops antibody medicines, including the pipeline programs IMB-101 and IMB-102.
IMBiologics (Ticker: 493280 KS) researches and develops antibody medicines through a full-cycle drug development system, including programs IMB-101 and IMB-102. The company has secured technology transfer agreements for IMB-101 and IMB-102. The offering consists entirely of newly issued shares. The offering allocates 75% of shares to institutional investors and 25% to the general public. Institutional demand was reported at a competition ratio of 839.23 to 1.
The scheduled listing date on Korea Exchange (KOSDAQ) was March 20, 2026. The proposed offering comprises 2,000,000 shares at an indicative price of KRW 26000 per share. The base offering would represent KRW 52.00 billion, approximately $39.11 million in gross proceeds, excluding any unexercised over-allotment. The indicated IPO market capitalization is KRW 384.50 billion, approximately $289.18 million.
Korea Investment & Securities and Shinhan Investment & Securities are underwriters.
Prepared with IPOX® AI assistance. Information may contain errors.
Prepared with IPOX® AI assistance. Information may contain errors.